Victory Capital Management
PCVX icon

Victory Capital Management’s Vaxcyte PCVX Stock Holding History

Victory Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$26.2M Buy
460,306
+7,583
+2% +$442K 0.01% 787
2026
Q2 		$26.3M Sell
452,723
-49,134
-10% -$2.67M 0.01% 815
2026
Q1 		$29.2M Sell
501,857
-47,657
-9% -$2.59M 0.02% 739
2025
Q4 		$25.4M Buy
549,514
+234,622
+75% +$10.5M 0.01% 797
2025
Q3 		$11.3M Sell
314,892
-135,727
-30% -$4.5M 0.01% 1066
2025
Q2 		$14.7M Buy
450,619
+229,800
+104% +$7.53M 0.01% 987
2025
Q1 		$8.34M Sell
220,819
-82,737
-27% -$6.62M 0.01% 1118
2024
Q4 		$24.8M Buy
303,556
+48,516
+19% +$4.82M 0.02% 761
2024
Q3 		$29.1M Sell
255,040
-52,476
-17% -$4.73M 0.03% 685
2024
Q2 		$23.2M Buy
307,516
+26,641
+9% +$1.81M 0.02% 751
2024
Q1 		$19.2M Sell
280,875
-98,532
-26% -$6.82M 0.02% 834
2023
Q4 		$23.8M Sell
379,407
-51,542
-12% -$2.68M 0.03% 712
2023
Q3 		$22M Sell
430,949
-31,355
-7% -$1.55M 0.03% 715
2023
Q2 		$23.1M Buy
462,304
+69,055
+18% +$3.27M 0.03% 720
2023
Q1 		$14.7M Buy
393,249
+325,536
+481% +$13.8M 0.02% 891
2022
Q4 		$3.25M Buy
67,713
+11,693
+21% +$459K ﹤0.01% 1309
2022
Q3 		$1.34M Sell
56,020
-17,610
-24% -$446K ﹤0.01% 1603
2022
Q2 		$1.6M Sell
73,630
-15,380
-17% -$356K ﹤0.01% 1541
2022
Q1 		$2.15M Buy
+89,010
New +$1.94M ﹤0.01% 1473
2020
Q4 		– Sell
-5,102
Closed -$252K – 2574
2020
Q3 		$252K Buy
+5,102
New +$203K ﹤0.01% 2222

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 20.64% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return

Victory Capital Management's PCVX Position: Q3 2026 in Review

Victory Capital Management increased its Vaxcyte (PCVX) stake by 1.7% in Q3 2026, buying an estimated $442K and bringing the position to 460,306 shares worth $26.2M. The position accounts for 0.01% of the portfolio, ranked #787.

Victory Capital Management first reported a position in PCVX in Q3 2020 and has held it in 20 quarters since. The position peaked at $29.2M in Q1 2026. 202 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.

  • Victory Capital Management held 460,306 shares of Vaxcyte worth $26.2M as of Q3 2026.
  • Victory Capital Management bought 7,583 Vaxcyte shares in Q3 2026, an estimated $442K.
  • Vaxcyte made up 0.01% of Victory Capital Management's portfolio in Q3 2026, its #787 holding.
  • Victory Capital Management first reported a position in Vaxcyte in Q3 2020 and has held it in 20 quarters since.
  • Victory Capital Management's Vaxcyte position peaked at $29.2M in Q1 2026.
  • 202 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.

Based on Victory Capital Management's 13F filing for Q3 2026, filed 10 Nov 2026.